Literature DB >> 34339851

Left bundle branch-optimized cardiac resynchronization therapy (LOT-CRT): Results from an international LBBAP collaborative study group.

Marek Jastrzębski1, Paweł Moskal2, Wim Huybrechts3, Karol Curila4, Praveen Sreekumar5, Leonard M Rademakers6, Shunmuga Sundaram Ponnusamy7, Bengt Herweg8, Parikshit S Sharma9, Agnieszka Bednarek2, Marek Rajzer2, Pugazhendhi Vijayaraman10.   

Abstract

BACKGROUND: Cardiac resynchronization therapy (CRT) based on the conventional biventricular pacing (BiV-CRT) technique sometimes results in broad QRS complex and suboptimal response.
OBJECTIVE: We aimed to assess the feasibility and outcomes of CRT based on left bundle branch area pacing (LBBAP, in lieu of the right ventricular lead) combined with coronary venous left ventricular pacing in an international multicenter study.
METHODS: LBBAP-optimized CRT (LOT-CRT) was attempted in nonconsecutive patients with CRT indications. Addition of the LBBA (or coronary venous) lead was at the discretion of the implanting physician, who was guided by suboptimal paced QRS complex, and/or on clinical grounds.
RESULTS: LOT-CRT was successful in 91 of 112 patients (81%). The baseline characteristics were as follows: mean age 70 ± 11 years, female 22 (20%), left ventricular ejection fraction 28.7% ± 9.8%, left ventricular end-diastolic diameter 62 ± 9 mm, N-terminal pro-B-type natriuretic peptide level 5821 ± 8193 pg/mL, left bundle branch block 47 (42%), nonspecific intraventricular conduction delay 25 (22%), right ventricular pacing 26 (23%), and right bundle branch block 14 (12%). The procedure characteristics were as follows: mean fluoroscopy time 27.3 ± 22 minutes, LBBAP capture threshold 0.8 ± 0.5 V @ 0.5 ms, and R-wave amplitude 10 mV. LOT-CRT resulted in significantly greater narrowing of QRS complex from 182 ± 25 ms at baseline to 144 ± 22 ms (P < .0001) than did BiV-CRT (170 ± 30 ms; P < .0001) and LBBAP (162 ± 23 ms; P < .0001). At follow-up of ≥3 months, the ejection fraction improved to 37% ± 12%, left ventricular end-diastolic diameter decreased to 59 ± 9 mm, N-terminal pro-B-type natriuretic peptide level decreased to 2514 ± 3537 pg/mL, pacing parameters were stable, and clinical improvement was noted in 76% of patients (New York Heart Association class 2.9 vs 1.9).
CONCLUSION: LOT-CRT is feasible and safe and provides greater electrical resynchronization as compared with BiV-CRT and could be an alternative, especially when only suboptimal electrical resynchronization is obtained with BiV-CRT. Randomized controlled trials comparing LOT-CRT and BiV-CRT are needed.
Copyright © 2021 Heart Rhythm Society. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Biventricular pacing; Cardiac resynchronization therapy; Heart failure; Left bundle branch area pacing; QRS narrowing

Mesh:

Year:  2021        PMID: 34339851     DOI: 10.1016/j.hrthm.2021.07.057

Source DB:  PubMed          Journal:  Heart Rhythm        ISSN: 1547-5271            Impact factor:   6.343


  11 in total

1.  Non-invasive assessment of ventricular electrical heterogeneity to optimize left bundle branch area pacing.

Authors:  Pugazhendhi Vijayaraman; Grace Hughes; Marilee Manganiello; Alicia Johns; Subham Ghosh
Journal:  J Interv Card Electrophysiol       Date:  2022-07-30       Impact factor: 1.759

2.  Dual-chamber ICD for left bundle branch area pacing: the cardiac resynchronization and arrhythmia sensing via the left bundle (cross-left) pilot study.

Authors:  Nicolas Clementy; Alexandre Bodin; Vincent Ah-Fat; Dominique Babuty; Arnaud Bisson
Journal:  J Interv Card Electrophysiol       Date:  2022-08-16       Impact factor: 1.759

3.  Acute Hemodynamic Effects of Simultaneous and Sequential Multi-Point Pacing in Heart Failure Patients With an Expected Higher Rate of Sub-response to Cardiac Resynchronization Therapy: Results of Multicenter SYNSEQ Study.

Authors:  Maciej Sterliński; Joanna Zakrzewska-Koperska; Aleksander Maciąg; Adam Sokal; Joaquin Osca-Asensi; Lingwei Wang; Vasiliki Spyropoulou; Baerbel Maus; Francesca Lemme; Osita Okafor; Berthold Stegemann; Richard Cornelussen; Francisco Leyva
Journal:  Front Cardiovasc Med       Date:  2022-05-12

Review 4.  Electrical management of heart failure: from pathophysiology to treatment.

Authors:  Frits W Prinzen; Angelo Auricchio; Wilfried Mullens; Cecilia Linde; Jose F Huizar
Journal:  Eur Heart J       Date:  2022-05-21       Impact factor: 35.855

5.  Conduction System Pacing: Where Are We Now?

Authors:  Imran Niazi
Journal:  J Innov Card Rhythm Manag       Date:  2022-01-15

6.  Amulet™ Shines and Protects; Pacing Battle Intensifies with "More Leads or No Leads"?

Authors:  Christopher R Ellis; Nicholas King
Journal:  J Innov Card Rhythm Manag       Date:  2022-01-15

7.  Clinical Outcomes of Permanent Left Bundle Branch Area Pacing in Patients With Left Bundle Branch Block and Left Ventricular Ejection Fraction >35 vs. ≤35.

Authors:  Zhixin Jiang; Tian Wu; Yixian Wu; Zenghong Chen; Wen Yang; Chongchong Chen; Xiujuan Zhou; Qijun Shan
Journal:  Front Cardiovasc Med       Date:  2022-03-17

8.  Overview of Current Strategies Aiming at Improving Response to Cardiac Resynchronization Therapy.

Authors:  Yakup Yunus Yamantürk; Başar Candemir; Emir Baskovski; Kerim Esenboğa
Journal:  Anatol J Cardiol       Date:  2022-05       Impact factor: 1.475

Review 9.  Alternative pacing strategies for optimal cardiac resynchronization therapy.

Authors:  Juan Hua; Qiling Kong; Qi Chen
Journal:  Front Cardiovasc Med       Date:  2022-09-27

10.  Left bundle branch area pacing in patients with heart failure and right bundle branch block: Results from International LBBAP Collaborative-Study Group.

Authors:  Pugazhendhi Vijayaraman; Oscar Cano; Shunmuga Sundaram Ponnusamy; Manuel Molina-Lerma; Joseph Y S Chan; Santosh K Padala; Parikshit S Sharma; Zachary I Whinnett; Bengt Herweg; Gaurav A Upadhyay; Faiz A Subzposh; Neil R Patel; Dominik A Beer; Agnieszka Bednarek; Grzegorz Kielbasa; Roderick Tung; Kenneth A Ellenbogen; Marek Jastrzebski
Journal:  Heart Rhythm O2       Date:  2022-05-14
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.